title: Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee.
authors.affiliation: Department of Nuclear Medicine, Bordeaux University Hospital, Bordeaux, France.
authors.forename: Charles
authors.identifier: 0000-0002-3889-755X
authors.initials: C
authors.lastname: Mesguich
authors.affiliation: Department of Nuclear Medicine, Institut Bergonié Cancer Centre, Bordeaux, France.
authors.forename: Anne-Laure
authors.initials: AL
authors.lastname: Cazeau
authors.affiliation: Department of Hematological Oncology, Bordeaux University Hospital, Bordeaux, France.
authors.forename: Krimo
authors.initials: K
authors.lastname: Bouabdallah
authors.affiliation: Department of Nuclear Medicine, Bordeaux University Hospital, Bordeaux, France.
authors.forename: Elif
authors.initials: E
authors.lastname: Hindié
mesh_terms: D002648:Child; D019788:Fluorodeoxyglucose F18; D006689:Hodgkin Disease; D006801:Humans; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: Hodgkin lymphoma; imaging; lymphomas; positron emission tomography; prognostic factors